达拉非尼联合曲美替尼再挑战治疗既往BRAF和MEK抑制剂经治的晚期BRAFV600突变黑色素瘤:一项开放标签、单臂、双中心、2期临床试验
这项开放标签、单臂、双中心2期研究在比利时纳入25例既往BRAF抑制剂(±MEK抑制剂)进展且停药至少12周的BRAFV600突变黑色素瘤患者,给予达拉非尼150 mg每日两次口服联合曲美替尼2 mg每日一次口服。主要终点为研究者评估的任意时间总体缓解率,8例(32%,95%CI 15-54)达部分缓解,10例(40%,95%CI 21-61)疾病稳定;再挑战耐受良好,无预期外或4/5级治疗相关不良事件。
要点
- 25例既往BRAF抑制剂进展的BRAFV600突变黑色素瘤患者接受达拉非尼联合曲美替尼再挑战,8例(32%)达部分缓解。
- 10例(40%)疾病稳定,再挑战耐受良好,无预期外或4/5级治疗相关不良事件。
- 3级不良事件2例(8%):脂膜炎1例、发热1例;1例因2级发热症状诱发肾上腺危象为严重不良事件。
核心结论
- 达拉非尼联合曲美替尼再挑战在既往BRAF抑制剂进展的患者中显示出抗肿瘤活性,再挑战是这些患者的潜在新治疗选择。
研究设计与样本
- 开放标签、单臂、双中心、2期学术研究,在比利时开展,纳入25例年龄18岁及以上、既往BRAF抑制剂(联合或不联合MEK抑制剂)进展且停药至少12周的BRAFV600突变黑色素瘤患者。
- 治疗方案为达拉非尼150 mg口服每日两次联合曲美替尼2 mg口服每日一次。
- 主要终点为研究者评估的任意时间总体缓解比例,即按RECIST 1.1版在首次记录缓解后至少28天两次确认的完全缓解或部分缓解,分析在意向治疗人群中进行。
- 研究正在进行但已停止招募患者,临床试验注册号NCT02296996。
主要发现
- 2014年4月5日至2016年2月2日共25例患者入组并开始治疗。
- 8例(32%,95%CI 15-54)记录到部分缓解,其中6例既往达拉非尼联合曲美替尼治疗进展、2例既往BRAF抑制剂单药治疗进展。
- 10例(40%,95%CI 21-61)疾病稳定。
- 再挑战耐受良好,无预期外或4级或5级治疗相关不良事件;3级不良事件2例(8%),分别为脂膜炎1例和发热1例。
- 研究期间发生的严重不良事件为1例患者因2级发热症状诱发肾上腺危象,停用达拉非尼和曲美替尼后缓解;无患者因研究治疗死亡。
关键数值与推荐
- 主要终点总体缓解:8/25例(32%,95%CI 15-54)。
- 疾病稳定:10/25例(40%,95%CI 21-61)。
- 3级不良事件:2/25例(8%),脂膜炎1例、发热1例。
临床怎么用
- 作者认为,对既往BRAF抑制剂进展的患者,达拉非尼联合曲美替尼再挑战显示出抗肿瘤活性,再挑战是这些患者的潜在新治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with BRAFV600-mutant melanoma benefit from treatment with the combination of BRAF and MEK inhibitors, but resistance and disease progression develops in most patients. Preclinical studies and case studies have indicated that acquired resistance to BRAF inhibition can be reversible. We aimed to assess the anti-tumour activity of rechallenge with BRAF plus MEK inhibition in a prospective clinical trial. METHODS: In this open-label, single arm, dual-centre, phase 2 academic study in Belgium, patients aged 18 years or older with BRAFV600-mutant melanoma who had previously progressed on BRAF inhibitors (with or without MEK inhibitors) and were off-treatment for at least 12 weeks, were treated with dabrafenib 150 mg orally twice per day plus trametinib 2 mg orally once per day. The primary endpoint was the proportion of patients with investigator-assessed overall response at any time (defined as complete response or partial response according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 confirmed on two occasions, at least 28 days after the first response was recorded). Analyses were done in the intention-to-treat population. The study is ongoing but no longer recruiting patients. This trial is registered with ClinicalTrials.gov, number NCT02296996. FINDINGS: Between April 5, 2014, and Feb 2, 2016, 25 patients were enrolled and initiated treatment in our study. A partial response was documented in eight (32%) of 25 patients (95% CI 15-54; six patients had progressed on previous treatment with dabrafenib plus trametinib and two patients had progressed on previous BRAF inhibitor monotherapy). Stable disease was noted in ten patients (40%; 95% CI 21-61). Rechallenge with dabrafenib plus trametinib was well tolerated. There were no unexpected or grade 4 or 5 treatment-related adverse events. Grade 3 adverse events occurred in two patients (8%; panniculitis [n=1] and pyrexia [n=1]). Serious adverse events which occurred on study were one patient with an Addison crisis triggered by grade 2 pyrexia symptoms that resolved after discontinuation of dabrafenib and trametinib. No patients died as a result of study treatment. INTERPRETATION: Rechallenge with dabrafenib plus trametinib showed anti-tumour activity in patients who had previously progressed on BRAF inhibitors and as such, rechallenge represents a potential new treatment option for these patients. FUNDING: Vlaamse Liga Tegen Kanker, Novartis.
引用
- Schreuer M, Jansen Y, Planken S, et al. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. Lancet Oncol. 2017. PMID: 28268064. doi:10.1016/S1470-2045(17)30171-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。